Choice of neoadjuvant endocrine agent
There have been three large randomized controlled trials comparing tamoxifen to aromatase inhibitors; each demonstrating either superiority or non-inferiority of aromatase inhibitors in the neoadjuvant setting [
16,
19,
59,
60]. Tamoxifen is a long-standing treatment for breast cancer; however, it may lead to serious adverse effects including thromboembolism and endometrial cancer [
59]. Additionally, tamoxifen resistance is not uncommon, yet approximately one-third of patients with resistance to tamoxifen will still benefit from aromatase inhibition [
61]. Aromatase inhibitors block the peripheral conversion of androgen to estrogen, reducing circulating estrogen levels by up to 90% [
62].
The P024 trial is the largest trial comparing neoadjuvant tamoxifen and letrozole in postmenopausal women with ER
+ breast cancer who were ineligible for BCS [
16,
59]. Letrozole led to a significantly greater objective response rate (ORR) and rate of BCS (Table
1) [
59]. Response rates in the letrozole group were higher than for tamoxifen in all Allred Scores from 3 to 8, demonstrating letrozole’s superiority independently of ER expression level [
36]. The most common adverse events in this trial were hot flushes and nausea, which occurred equally with tamoxifen and letrozole (57% of patients in each group) [
59].
Table 1
Tamoxifen vs. aromatase inhibitors in the neoadjuvant setting
P024 Trial Eiermann et al. 2001 [ 59] | 4 | Letrozole 2.5 or tamoxifen 20 | 324 | 1. pCR: 1.3% letrozole; 1.8% tamoxifen 2. ORR (clinical palpation): 55% letrozole; 36% tamoxifen (p < 0.0001). ER+subgroup: 60% letrozole; 41% tamoxifen. 3. BCS: 45% letrozole; 35% tamoxifen (p = 0.022) | Monthly clinical palpation and ultrasound. Mammography at baseline and prior to surgery. |
PROACT Cataliotti et al. 2006 [ 60] | 3 | Anastrozole 1 or tamoxifen 20 ± NCT | 451 | 1. pCR: NR. 2. ORR (clinical palpation): 49.7% anastrozole; 39.7% tamoxifen (p > 0.5, NET only) 3. BCS: 43% anastrozole; 30.8% tamoxifen (p = 0.04, NET only) | Ultrasound and caliper measurements at baseline and 3 months. |
IMPACT Smith et al. 2005 [ 19] | 3 | Anastrozole 1 or tamoxifen 20 or combination | 330 | 1. pCR: NR. 2. ORR (clinical palpation): 37% anastrozole; 36% tamoxifen; 39% combination (p = 0.87) 3. BCS: 44% anastrozole; 31% tamoxifen; 24% combination (p = 0.23, mastectomy at baseline) | Clinical caliper measurements and ultrasound at baseline, 2, 6 and 12 weeks. |
Akashi-Tanaka et al. 2007 [ 63] | 5 (Anastrozole) or 4 (Tamoxifen) | Anastrozole 1 or tamoxifen 20 | 45 | 1. pCR: not reported. 2. ORR (clinical palpation): 76.5% anastrozole; 46.4% tamoxifen 3. BCS: not reported. | Monthly clinical assessment. |
Semiglazov et al. 2005 [ 64] | 3 | Exemestane 25 or tamoxifen 20 | 151 | 1. pCR: 2.6% exemestane; 2.7% tamoxifen 2. ORR (clinical palpation): 76.3% exemestane; 40% tamoxifen (p = 0.05) 3. BCS: 36.8% exemestane; 20% tamoxifen (p = 0.05) | Not reported. |
Two large trials compared neoadjuvant tamoxifen and anastrozole (Table
1). In terms of ORR, both the PROACT and IMPACT trials demonstrated non-inferiority of anastrozole to tamoxifen [
19,
60]. In terms of BCS, the PROACT trial showed a significantly higher rate in patients taking anastrozole; however, this rate did not reach significance in the IMPACT trial (Table
1) [
19,
60]. Hot flushes were the most common adverse event on both medications; however, anastrozole had a lower rate of vaginal discharge and thromboembolic events in the IMPACT trial [
19]. Additional studies which demonstrate the superiority of aromatase inhibitors in comparison to tamoxifen are summarized in Table
1 [
63,
64].
There have also been a number of trials comparing different aromatase inhibitors, or aromatase inhibitors with fulvestrant, a selective estrogen receptor degrader (Table
2) [
26]. Overall, these studies have not been able to demonstrate superiority of one aromatase inhibitor over another. In terms of ORR, the largest trial (Z1031 trial) did not demonstrate a significant difference between exemestane (62.9%), letrozole (74.8%), and anastrozole (69.1%) (Table
2) [
53,
54]. Other studies comparing aromatase inhibitors also did not demonstrate superiority of any one agent (Table
2) [
28,
65,
66]. In terms of the BCS rate, there was no significant difference found between the types of aromatase inhibitors or fulvestrant (Table
2) [
28,
53,
54,
65,
66].
Table 2
Comparison of aromatase inhibitors and fulvestrant
Z1031 trial. Ellis et al. 2011 and 2017 [ 53, 54] | 4 | Exemestane 25 or letrozole 2.5 or anastrozole 1 | 377 | 1. pCR: 1.6% (AI 16 weeks); 5.7% (switched to chemotherapy at 2 weeks) 2. ORR (clinical palpation): 62.9% exemestane; 74.8% letrozole; 69.1% anastrozole. 3. BCS: 51% (patients mastectomy at baseline); 83% (patients marginal for BCS) | Monthly physical examination, toxicity assessment, and tumor assessment. |
CARMINA 02 Lerebours et al. 2016 [ 28] | 4 or 6 | Anastrozole 1 or fulvestrant 500 mg/month | 116 | 1. pCR: NR. 2. ORR (clinical palpation): 52.6% anastrozole; 36.8% fulvestrant. 3. BCS: 57.6% anastrozole; 50% fulvestrant (p = 0.5) | Clinical assessment, ultrasound, and MRI at baseline, 1 month, and 4 months. |
Grassadonia et al. 2014 [ 65] | Mean 5.7 | Anastrozole 1 or exemestane 25 or letrozole 2.5 | 144 | 1. pCR: 1.4% 2. ORR (clinical palpation): 86.6% (9.6% CR and 77% PR) 3. BCS: 84% (ineligible for BCS at baseline) | Caliper measurement at baseline, monthly, and before surgery. |
FIRST Robertson et al. 2009 [ 66] | Until progression | Anastrozole 1 or fulvestrant 500 mg/month | 205 | 1. pCR: NR. 2. ORR (clinical palpation): 35.5% anastrozole; 36% fulvestrant (p = 0.947) 3. BCS: NR. | Clinical and radiological tumor assessment every 12 ± 2 weeks until progression. |
Following the determination that all three aromatase inhibitors showed biological equivalence, the Z1031 trial created an extension study known as Z1031B [
53,
54]. In the Z1031B trial, patients who had a Ki67 > 10% after 2 to 4 weeks of NET were switched to chemotherapy in an attempt to increase the rate of pCR [
53]. Based on the IMPACT trial and Preoperative Letrozole study, patients with a Ki67 > 10% were found to have a < 2% chance of obtaining PEPI = 0 and, hence, avoiding adjuvant chemotherapy [
19,
53,
67]. Of the patients who switched to NCT, only 5.7% (2 patients) went on to achieve a pCR [
53]. In patients who had a 2-week Ki67 < 10% and received 16 weeks of NET, the pCR rate was 1.6% and the PEPI = 0 rate was 34.4% [
53].
The ALTERNATE trial is a phase III trial currently in recruitment which aims to compare anastrozole, fulvestrant, or their combination and identify women at a low risk of recurrence based on the PEPI [
26]. After 4 weeks of treatment, women with a Ki67 > 10% will be switched to NCT, and only women with a PEPI = 0 post-surgery will receive adjuvant endocrine therapy [
26].
Recommendation: If suitable for NET, post-menopausal patients with ER+ and/or PgR+ LABC should receive aromatase inhibitors as first-line neoadjuvant therapy. The choice of aromatase inhibitor should be guided by local clinical practice and has not been shown to affect outcomes. |
Duration of neoadjuvant endocrine therapy
Despite the advantages of aromatase inhibitors being clearly highlighted in the P024 and Z1031A trials, there is continual limited use by physicians [
68]. A study from the USA revealed only 3.1% of women with ER and/or PgR
+ breast cancer received NET compared to 24.7% who received NCT [
69]. However, this figure has slowly increased from 2.3% (2004) to 3.5% (2014), with women treated in academic rather than community centers more likely to receive NET [
69]. In addition, this study found women were more likely to receive NET if they were > 60 years old and had tumors with a lower grade or stage III disease [
69]. Potential barriers to widespread adoption of NET include the heterogenous nature of patient responses, and the long duration required to achieve a clinical response [
53]. The reluctance to introduce NET into clinical practice may also represent the poor response rates seen when treatment is carried out for a duration of only 3 to 4 months [
30]. In comparison to NCT, NET has more gradual effect on the tumor and an extended treatment period is usually required in order to appreciate the maximum clinical response [
70].
The optimal duration of NET that should be administered to postmenopausal patients with ER
+ breast cancer has not yet been determined or incorporated into clinical guidelines [
18,
27,
71‐
73]. The majority of NET randomized trials use a treatment duration of 3 to 4 months, which is largely arbitrary and related to historical studies of tamoxifen and chemotherapy [
30,
73]. At the 2013 St. Gallen breast cancer conference, 62.2% of panelists supported NET being given until maximal response [
74,
75]. An additional 26.7% of panelists supported a duration of 4 to 8 months, while only 11.1% supported the current duration of 3 to 4 months [
75]. One of the major concerns of extending NET until maximal response is the risk of disease progression. A study by Carpenter et al. aiming to identify the optimal duration of letrozole therapy had a low progression rate of 6.5% [
30]. Similarly, a study of neoadjuvant exemestane showed a 7.7% progression rate at 4 months, increasing to only 8% at 6 months of treatment [
76]. Despite the evidence, 4 years on at the 2017 St. Gallen conference, uptake of NET remained suboptimal with the panel stating that “Neoadjuvant ET in postmenopausal women with ER
+ stage II/III tumors is currently underused, although it shows low toxicity” [
68]. Six years later at the 2019 St. Gallen International Breast Cancer Conference, there is extremely limited attention given to the neoadjuvant treatment of ER
+ tumors and no clinical guidelines or recommendations are made [
39].
Recently, there have been several small studies aiming to investigate the optimal duration of NET, only two of which were randomized trials. In the four studies where the duration of NET was extended to 12 months, the ORR’s ranged from 76.8 to 95%, and the rate of BCS was 45 to 87.5% (Table
3) [
27,
29,
30,
73]. In contrast, the large PROACT and IMPACT trials, discussed previously, used a duration of 3 months and reported an ORR of only 49.7 and 37%, respectively, with BCS rates of 43 and 44% [
19,
60]. A single-center study demonstrating the effectiveness of 12 months of letrozole found that in addition to the high ORR of 88%, 13% of patients achieved a pCR and less than 10% of patients progressed [
29]. A second single-center study provided further evidence for increased duration of letrozole treatment, with a pCR rate of 2.5% at 4 months, 5% at 8 months, and 17.5% at 12 months [
27]. This indicates that the short duration of conventional NET may be the reason behind the low pCR rate frequently observed [
27]. A longitudinal phase IV study demonstrated that the median treatment time to allow BCS in previously ineligible patients was 7.5 months, suggesting the conventional duration of 4 months is not optimal [
30]. The proportion of patients who became candidates for BCS increased with time, with 66% of patients suitable after 12 months of letrozole treatment [
30]. This was an approximately twofold increase in eligibility for BCS when treatment was extended from 4 to 8 months [
30]. An earlier phase II trial from 2012 studied letrozole administration over the period of 4 to 12 months and found that maximal response was achieved in a median time of 4.2 months [
73]. However, 37% of patients continued to improve beyond 6 months and achieved a maximal response within 6 to 12 months, with the ORR increasing from 55% at 4 months to 76.8% at the conclusion of the study (Table
3) [
73]. Other studies which demonstrate the benefit of extending NET are outlined in Table
3 [
71,
72]. Interestingly, in the study by Krainick-Strobel et al., of 5 patients who had no change in clinical palpation at 4 months, 1 went on to achieve a complete response and 2 a partial response at 8 months of treatment with letrozole [
72]. A retrospective analysis of data in the USA showed that in women who received NET for 1 to 3 months, 20.6% had their tumors down-staged, compared to down-staging in 34.9% of those who received NET for 12 to 24 months [
69].
Table 3
Duration of neoadjuvant endocrine therapy
| 12 | Letrozole 2.5 | 42 | 1. pCR: 14.3% operated cases; 13% overall 2. ORR (clinical palpation): 88% 3. BCS: 45% | Clinical palpation every 3 months. Imaging as necessary. |
Carpenter et al. 2014 [ 30] | Up to 12 | Letrozole 2.5 | 139 | 1. pCR: not reported. 2. ORR (clinical palpation): 85% (3.2% CR and 81.5% PR) 3. BCS: 66% at 12 months (all ineligible at baseline) | Clinical examination and bimodal ultrasound every 2 months until BCS. |
| Randomized to 4, 8, or 12 | Letrozole 2.5 | 120 | 1. pCR: 2.5% 4 months; 5% 8 months and 17.5% 12 months. 2. ORR (clinical palpation): 45% 4 months; 86.8% 8 months; 95% 12 months. 3. BCS: 80% 4 months; 85% 8 months; 87.5% 12 months. | Monthly clinical palpation (caliper). Mammography and ultrasound at baseline and before surgery. |
Llombart-Cussac et al. 2012 [ 73] | 3 to 12 | Letrozole 2.5 | 70 | 1. pCR: 0% 2. ORR (clinical palpation): 76.8% (25% CR and 51.8% PR) 3. BCS: 43% | Monthly clinical examination. Mammogram and ultrasound every 8 weeks for first 4 months. |
| 3 to > 24 months | Letrozole 2.5 | 182 | 1. pCR: NR. 2. ORR (clinical palpation): 69.8% 3 months; 83.5% > 3 months. 3. BCS: 60% 3 months; 72% > 3 months. | Clinical measurement and ultrasound at 0, 2, 6, and 12 weeks. Mammogram at 0 and 12 weeks. 3 monthly review thereafter. |
Krainick-Strobel et al. 2008 [ 72] | 4 to 8 | Letrozole 2.5 | 32 | 1. pCR: NR. 2. ORR (clinical palpation): 55% 4 months; 72.4% 8 months. 3. BCS: 75.9% (all ineligible at baseline) | Monthly clinical examination, ultrasound and mammogram. |
TEAM IIA Fontein et al. 2014 [ 70] | 3 to 6 | Exemestane 25 | 102 | 1. pCR: 0.98% 2. ORR (clinical palpation): 58.7% 3 months; 68.3% > 3 months (p = 0.031). 3. BCS: feasibility improved 61.8% to 70.6%. | Monthly clinical palpation. 3 monthly MRI, mammogram or ultrasound. |
PTEX46 Hojo et al. 2013 [ 76] | 4 or 6 | Exemestane 25 | 52 | 1. pCR: 0% 4 months; 4% 6 months. 2. ORR (clinical palpation): 42.3% 4 months; 48% 6 months (p = 0.89). 3. BCS: 50% 4 months; 48% 6 months. | Monthly caliper measurement and toxicity assessment. Ultrasound and mammogram if progression suspected. |
Two studies have investigated the optimal duration of NET using exemestane. Exemestane is an irreversible, steroidal aromatase inhibitor which may have fewer adverse effects on the metabolism of lipids and formation of bone when compared to letrozole or anastrozole [
77,
78]. The PTEX46 randomized phase II trial found no significant difference in the ORR at 4 or 6 months and suggested the optimal duration of NET is around 4 months (Table
3) [
76]. In contrast, the TEAM IIA trial found a significant increase in ORR from 3 to 6 months (Table
3) and concluded that in patients without progressive disease, extending exemestane treatment from 3 to 6 months improves clinical outcomes without increased toxicity [
70].
A concern in recommending extended durations of NET is the challenge in evaluating treatment response, coupled with the possibility of disease progression. Although most studies evaluating primary endocrine treatment have generally compared surgery +/− adjuvant endocrine therapy, with endocrine treatment alone, and therefore represent a different paradigm to NET followed by surgery +/− adjuvant endocrine therapy, it is valuable to note that these studies generally support the safety of NET to at least 12 months if only ER
+ cases are considered. Reviewed by Macaskill et al. [
79] and Pepping et al. [
80], it is important to note that most trials of primary endocrine treatment without surgery were not focused on LABC, and earlier trials did not select for ER positivity. Trials that selected on ER positivity found no difference in rates of recurrence and disease-specific outcome [
79,
80]. The 20-year follow-up report of the Nottingham study of 153 fit elderly patients with ER
+ breast cancer < 5 cm, randomized to primary tamoxifen or mastectomy with adjuvant tamoxifen [
81], revealed no difference in regional recurrence, metastasis, disease-specific, or overall survival between groups. Moreover, while locoregional control was poorer long-term in the no surgery cohort, there was no difference between surgery and no surgery groups until at least 18 to 24 months [
81]. This is in agreement with Willsher who reported a progression rate of 3% at 6 months of primary tamoxifen in a cohort selected for high ER, and just 16% requiring surgery after 3 years [
82]. Moreover, partial or complete response at 6 months was a strong predictor of excellent control at 3 years. Mustacchi et al. compared outcomes after primary endocrine therapy with tamoxifen, to surgery followed by adjuvant tamoxifen, in 474 women aged 70 and older [
83,
84]. No difference in disease-specific survival was observed between groups after 13 years, and although the progression rate was significantly greater in the tamoxifen only group at 80 months, there was no difference between groups at 12 months [
83]. These studies suggest that NET for up to 12 months is safe with close monitoring of tumor burden. Treatment beyond 12 months should be considered with caution.
Recommendation: NET should be continued for at least 6 months. In responders at 6 months, NET should be continued until a maximal clinical response is achieved. The best method to determine “maximal response” in clinical practice is complex and not yet standardized. |
Future directions
Recent studies looking at combining aromatase inhibitors with novel therapies to overcome endocrine resistance have been promising. Phosphatidylinositol 3-kinase (PI3K) inhibitors, including alpelisib and taselisib, have been combined with aromatase inhibitors in a number of recent trials due to the involvement of PI3K-AKT-mTOR pathway upregulation in endocrine resistance [
85,
86]. The large randomized phase II LORELEI trial recruited 334 patients with early-stage ER
+ breast cancer to letrozole plus taselisib or letrozole plus placebo and demonstrated a significant improvement in ORR in the letrozole plus taselisib group [
86].
Of recent interest has been the testing of CDK4/6 inhibitors, as these agents have been shown to enhance the activity of aromatase inhibitors and fulvestrant in advanced disease. The randomized phase II PALLET trial investigated the addition of palbociclib, a CDK4/6 inhibitor, to neoadjuvant letrozole in postmenopausal women with ER
+ breast cancer [
87]. This study found that the addition of a CDK4/6 inhibitor led to a significant reduction in proliferation measured by Ki67, compared to letrozole alone, but no significant improvement in clinical response rates over the 14 week study period [
87]. The NeoPAL trial demonstrated that this combination of palbociclib and letrozole produced an almost identical rate of clinical response and rate of BCS compared to patients receiving chemotherapy [
88]. In the neoMONARCH study which combined abemaciclib with anastrozole, results have shown significantly reduced levels of Ki67 with the CDK4/6 inhibitor with or without anastrozole, compared to anastrozole alone over 14 weeks of therapy [
89]. This study also observed an increase in gene expression associated with immune activation at 2 weeks, but only a modest increase in radiological response rates [
89]. The CORALLEEN trial was a randomized phase II trial of 106 patients investigating ribociclib plus letrozole vs. chemotherapy in post-menopausal women with hormone receptor-positive breast cancer of the luminal B subtype [
90]. At the end of the 6 months of the CORALLEEN trial the rate of patients achieving a PEPI of 0 was 17.3% with chemotherapy and 22.4% with ribociclib and letrozole [
90]. Especially when combining with CDK4/6 inhibitors, NET can achieve high rates of clinical response, even in luminal B patients, as compared with chemotherapy [
87,
88,
90]. This is in stark contrast to previous thoughts that NET should be for luminal A patients only. Therefore, the benefit of combination therapies is twofold; firstly, they can increase response in luminal A patients, and secondly, they have expanded the patient population to be considered for NET, sparing the toxicities of chemotherapy.
CDK4/6 inhibitors are approved, in Australia, Europe, and the USA, for treatment of ER
+ metastatic disease in combination with endocrine therapies. While available for LABC, they are not broadly accessible. Currently, ribociclib and palbociclib are available for use in Australia for patients with LABC; however, they are restricted to patients with disease that is deemed inoperable from the outset. These agents are not options for other locally advanced breast cancers where the aim of NET might be to facilitate more restricted breast-conserving surgery or targeted axillary dissection. Investigational treatment strategies combining other targeted agents (including PI3K inhibitors, mTOR inhibitors, and EGFR inhibitors) with endocrine therapies are currently continuing in various clinical trials. In future trial designs, it would be of interest to study not only other novel drug combinations but also to test these combinations over varying treatment durations. Finally, the observation that adding CDK4/6 inhibitors to NET might stimulate anti-tumor immunity [
89,
91], as has been observed with some chemotherapy agents [
92,
93], suggests that patients with ER
+ LABC could see improved benefit from second-line immunotherapy approaches, while avoiding cytotoxic chemotherapies. Future clinical trials combining NET and novel targeted agents would benefit from including this outcome measure.